TECH

58.63

0.17% -0.10

After Hours: 58.63

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $58.63, with a volume of 1.47M. It is down -0.17% in the last 24 hours and down -5.05% over the past month.

Previous Close:

$58.73

Open:

$57.98

24h Volume:

1.47M

Relative Volume:

1.03

Market Cap:

$9.65B

Revenue:

$1.17B

Net Income/Loss:

$150.71M

P/E Ratio:

62.37

EPS:

0.94

Net Cash Flow:

$245.03M

1W Performance:

-4.00%

1M Performance:

-5.05%

6M Performance:

-26.65%

1Y Performance:

-16.71%

1-Day Range:

$56.70

$59.20

1-Week Range:

$56.70

$61.86

52-Week Range:

$56.60

$85.57

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

(612) 379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	58.63	9.65B	1.17B	150.71M	245.03M	0.94
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

10:00 AM

Bio-Techne Opens New Customer Experience Centre in Germany - Yahoo Finance

10:00 AM

05:12 AM

3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Yahoo Finance

05:12 AM

Mar 28, 2025

Research Tools & Consumables Stocks Q4 Earnings: Bio-Techne (NASDAQ:TECH) Best of the Bunch - Yahoo Finance

Mar 28, 2025

Mar 26, 2025

Bio-Techne to Open New Customer Facility in Germany - Marketscreener.com

Mar 26, 2025

Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany - Yahoo Finance

Mar 26, 2025

Mar 24, 2025

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting - Quantisnow

Mar 24, 2025

Game-Changing Cancer Detection Technology: RNAscope Shows Superior Results in Multiple Tumors - Stock Titan

Mar 24, 2025

Mar 19, 2025

Bio-Techne Earnings Preview: What to Expect - MSN

Mar 19, 2025

Evercore ISI Group Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation - MSN

Mar 19, 2025

Mar 18, 2025

Evercore ISI sets Bio-Techne stock Outperform with $75 target By Investing.com - Investing.com South Africa

Mar 18, 2025

6 Analysts Assess Bio-Techne: What You Need To Know - Benzinga

Mar 18, 2025

Evercore ISI sets Bio-Techne stock Outperform with $75 target - Investing.com

Mar 18, 2025

Mar 17, 2025

Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future - TipRanks

Mar 17, 2025

Bio-Techne (NASDAQ:TECH) shareholders have earned a 8.3% CAGR over the last five years - Yahoo Finance

Mar 17, 2025

Mar 13, 2025

Bio-Techne Co. (NASDAQ:TECH) Receives $82.14 Consensus Price Target from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025

Bio Techne at Barclays Conference: Strategic Growth Amid Market Challenges - Investing.com

Mar 12, 2025

TECH Stock Might Rise Following the Leo Shipping Announcement - Nasdaq

Mar 12, 2025

Mar 11, 2025

Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 11, 2025

Bio-Techne at Leerink’s Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com India

Mar 11, 2025

Techne Corp stock hits 52-week low at $58.94 amid market shifts - Investing.com India

Mar 11, 2025

Techne Corp stock hits 52-week low at $58.94 amid market shifts By Investing.com - Investing.com South Africa

Mar 11, 2025

GC Wealth Management RIA LLC Takes $805,000 Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Mar 11, 2025

Mar 10, 2025